---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-000588"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:20:00.892819+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics CSO Charles H. Randall resigns effective Dec 31, 2021

## Summary
- Charles H. Randall resigned as Chief Strategy Officer on December 31, 2021.
- Company and Mr. Randall are finalizing terms of release and severance under his employment agreement.
- No replacement or interim appointment has been announced.

## SEC filing metadata
- accession: 0001493152-22-000588
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000149315222000588/0001493152-22-000588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000149315222000588/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-000588
- JSON: https://secwatch.observer/filing/0001493152-22-000588.json
- Plain text: https://secwatch.observer/filing/0001493152-22-000588.txt

## Key facts
- Executive change
  Charles H. Randall resigned as Chief Strategy Officer at SAB Biotherapeutics, Inc..
  - Action: resigned
  - Role: Chief Strategy Officer
  source text: On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000149315222000588/0001493152-22-000588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.